LGND - Ligand Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (5Y Monthly) 1.24
52-Week Change 3-21.18%
S&P500 52-Week Change 325.78%
52 Week High 3130.50
52 Week Low 384.45
50-Day Moving Average 3100.30
200-Day Moving Average 3102.22

Share Statistics

Avg Vol (3 month) 3329.46k
Avg Vol (10 day) 3320.08k
Shares Outstanding 517.56M
Float 15.75M
% Held by Insiders 14.03%
% Held by Institutions 1133.43%
Shares Short (Dec 30, 2019) 47.77M
Short Ratio (Dec 30, 2019) 426.72
Short % of Float (Dec 30, 2019) 447.88%
Short % of Shares Outstanding (Dec 30, 2019) 444.26%
Shares Short (prior month Nov 28, 2019) 47.67M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4Jul 01, 2010
Last Split Factor 21:6
Last Split Date 3Nov 18, 2010

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 388.69%
Operating Margin (ttm)24.60%

Management Effectiveness

Return on Assets (ttm)1.29%
Return on Equity (ttm)76.66%

Income Statement

Revenue (ttm)152.87M
Revenue Per Share (ttm)7.66
Quarterly Revenue Growth (yoy)-45.70%
Gross Profit (ttm)217.25M
Net Income Avi to Common (ttm)594.19M
Diluted EPS (ttm)28.29
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.15B
Total Cash Per Share (mrq)65.45
Total Debt (mrq)642.39M
Total Debt/Equity (mrq)75.52
Current Ratio (mrq)33.15
Book Value Per Share (mrq)48.43

Cash Flow Statement

Operating Cash Flow (ttm)10.57M
Levered Free Cash Flow (ttm)916.64M